Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 16, 2015

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions
Recurrent Uveal MelanomaStage IV Uveal Melanoma AJCC v7
Interventions
DRUG

Glembatumumab Vedotin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (25)

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

43210

Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic, Rochester

60451

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60462

University of Chicago Medicine-Orland Park, Orland Park

60611

Northwestern University, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Barnes-Jewish Hospital, St Louis

Washington University School of Medicine, St Louis

66160

University of Kansas Cancer Center, Kansas City

66205

University of Kansas Clinical Research Center, Fairway

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Hospital, Aurora

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85054

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

03756

Dartmouth Hitchcock Medical Center, Lebanon

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02363283 - Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | Biotech Hunter | Biotech Hunter